Dihydrotanshinone Attenuates LPS-Induced Acute Lung Injury in Mice by Upregulating LXRα

Inflammation. 2022 Feb;45(1):212-221. doi: 10.1007/s10753-021-01539-3. Epub 2021 Aug 31.

Abstract

Dihydrotanshinone (DIH) is an extract of Salvia miltiorrhiza Bunge. It has been reported that DIH could regulate NF-κB signaling pathway. The aim of this study was to investigate whether DIH could protect mice from lipopolysaccharide (LPS)-induced acute lung injury (ALI) in mice. In this study, sixty mice were randomly divided into five groups, one group as blank control group, the second group as LPS control group, and the last three groups were pre-injected with different doses of DIH and then inhaled LPS for experimental comparison. After 12 h of LPS treatment, the wet-dry ratio, histopathlogical changes, and myeloperoxidase (MPO) activity of lungs were measured. In addition, ELISA kits were used to measure the levels of TNF-α and IL-1β inflammatory cytokines in bronchoalveolar lavage fluids (BALF), and western blot analysis was used to measure the activity of NF-κB signaling pathway. The results demonstrated that DIH could effectively reduce pulmonary edema, MPO activity, and improve the lung histopathlogical changes. Furthermore, DIH suppressed the levels of inflammatory cytokines in BALF, such as TNF-α and IL-1β. In addition, DIH could also downregulate the activity of NF-κB signaling pathway. We also found that DIH dose-dependently increased the expression of LXRα. In addition, DIH could inhibit LPS-induced IL-8 production and NF-κB activation in A549 cells. And the inhibitory effects were reversed by LXRα inhibitor geranylgeranyl pyrophosphate (GGPP). Therefore, we speculate that DIH regulates LPS-induced ALI in mice by increasing LXRα expression, which subsequently inhibiting NF-κB signaling pathway.

Keywords: LPS; LXRα.; NF-κB; dihydrotanshinone.

MeSH terms

  • Acute Lung Injury / drug therapy*
  • Acute Lung Injury / etiology
  • Acute Lung Injury / metabolism
  • Animals
  • Anti-Inflammatory Agents / pharmacology*
  • Anti-Inflammatory Agents / therapeutic use
  • Biomarkers / metabolism
  • Furans / pharmacology*
  • Furans / therapeutic use
  • Lipopolysaccharides
  • Liver X Receptors / metabolism*
  • Male
  • Mice
  • Mice, Inbred BALB C
  • NF-kappa B / metabolism
  • Phenanthrenes / pharmacology*
  • Phenanthrenes / therapeutic use
  • Plant Extracts / pharmacology*
  • Plant Extracts / therapeutic use
  • Quinones / pharmacology*
  • Quinones / therapeutic use
  • Random Allocation
  • Signal Transduction
  • Up-Regulation / drug effects*

Substances

  • Anti-Inflammatory Agents
  • Biomarkers
  • Furans
  • Lipopolysaccharides
  • Liver X Receptors
  • NF-kappa B
  • Nr1h3 protein, mouse
  • Phenanthrenes
  • Plant Extracts
  • Quinones
  • dihydrotanshinone I